Wednesday, December 23, 2015

$ADMS Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease

Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

No comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...

Powered By

Powered By
Find Out MORE